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ABSTRACT
The demethylating agent 5-azacytidine (AZA) has proven its efﬁcacy in the treatment of myelodysplastic
syndrome and acute myeloid leukemia. In addition, AZA can demethylate FOXP3 intron 1 (FOXP3i1)
leading to the generation of regulatory T cells (Treg). Here, we investigated the impact of AZA on
xenogeneic graft-vs.-host disease (xGVHD) and graft-vs.-leukemia effects in a humanized murine model of
transplantation (human PBMCs-infused NSG mice), and described the impact of the drug on human T cells
in vivo. We observed that AZA improved both survival and xGVHD scores. Further, AZA signiﬁcantly
decreased human T-cell proliferation as well as IFNg and TNF-a serum levels, and reduced the expression
of GRANZYME B and PERFORIN 1 by cytotoxic T cells. In addition, AZA signiﬁcantly increased Treg
frequency through hypomethylation of FOXP3i1 as well as increased Treg proliferation. The latter was
subsequent to higher STAT5 signaling in Treg from AZA-treated mice, which resulted from higher IL-2
secretion by conventional T cells from AZA-treated mice itself secondary to demethylation of the IL-2 gene
promoter by AZA. Importantly, Tregs harvested from AZA-treated mice were suppressive and stable over
time since they persisted at high frequency in secondary transplant experiments. Finally, graft-vs.-
leukemia effects (assessed by growth inhibition of THP-1 cells, transfected to express the luciferase gene)
were not abrogated by AZA. In summary, our data demonstrate that AZA prevents xGVHD without
abrogating graft-vs.-leukemia effects. These ﬁndings could serve as basis for further studies of GVHD
prevention by AZA in acute myeloid leukemia patients offered an allogeneic transplantation.
Abbreviations: AZA, azacytidine; BM, bone marrow; DNMT, DNA methyltransferase; FOXP3, Forkhead box protein
P3; GVHD, graft-vs.-host disease; GZMB, granzyme B; H&E, hematoxylin and eosin; HCT, haematopoietic cell trans-
plantation; MLR, mixed lymphocyte reaction; NSG, NOD-scid IL-2Rgnull; PB, peripheral blood; PBMC, peripheral blood







Graft-vs.-host disease (GVHD) remains amajor limitation of allo-
geneic haematopoietic cell transplantation (allo-HCT).1 GVHD
comprises two syndromes: acute GVHD, which is a deregulated
inﬂammatory response causing skin, gastro-intestinal tract and/
or liver damage, and chronic GVHD, which generally occurs
beyond day 100 after transplantation, can affect virtually any tis-
sue, and sharesmany features with autoimmune diseases.2-5 Regu-
latory T cells (Tregs, deﬁned as CD4CCD25CFOXP3C T cells) are
not only required for the maintenance of tolerance to self-anti-
gens,6-8 but also play a critical role in the control of GVHD.9-14
Treg development and function requires the transcription
factor FOXP3. Indeed, mutations in the FOXP3 gene causing
Treg deﬁciency lead to a fatal autoimmune disorder known as
the IPEX syndrome.15 However, maintenance of Treg number
and function in mouse has been shown to also require the
demethylation of genes controlling the expression of molecules
implicated in Treg function such as IL2RA (CD25), TNFRSF18
(GITR), CTLA4 or FOXP3 itself.16 Notably, demethylation of a
regulatory region located in FOXP3 intron 1 (FOXP3i1) greatly
contributes to the stability of FOXP3 expression and to Treg
phenotype and functions, both in mice and humans.16-19
Demethylating agents such as 5-azacytidine (AZA) or decita-
bine are commonly used in the treatment of hematological malig-
nancies characterized by aberrant DNA methylation, such as
myelodysplastic syndromes or acute myeloid leukemia.20-22 While
AZA has cytostatic activity and induces apoptosis through double
break strands in DNA when used at high doses, it incorporates to
DNA and decreases DNAmethyltransferases (DNMT) levels caus-
ing widespread hypomethylation in daughter cells when used at
lower doses.23 Importantly, methylation array analyses in patients
treated with AZA have revealed a dramatic variability of demethyl-
ation responses from one patient to another and a partial restora-
tion of methylation pattern 2 weeks after AZA discontinuation.24
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Previous studies have demonstrated that demethylating
agents induce demethylation of FOXP3i1 and FOXP3 expres-
sion.25-30 Further, AZA prevented acute25,26 and chronic31
GVHD in mouse-to-mouse models of transplantation. How-
ever, in sharp contrast with these results, a study assessing the
impact of AZA administration on T cell subsets in patients
with myelodysplastic syndrome showed that, while AZA
increased FOXP3 expression, it induced cells with a phenotype
resembling Treg but that also produced IL-17.32
We and others have studied xenogeneic GVHD (xGVHD)
by infusing human peripheral blood mononuclear cells
(huPBMC) into NOD-scid IL-2Rg
null (NSG) mice.12,33-39 In that
model, human donor T cells react against murine MHC (and
particularly donor CD8C T cells against murine MHC-class 1
molecules).34 This model has many advantages in comparison
to classical murine models of GVHD, including donor genetic
diversity (which is critical for studying drugs with broad unspe-
ciﬁc hypomethylating activity, given their different hypomethy-
lating pattern in different patients), the use of human cells to
induce (and control) xGVHD (given important divergences
between murine and human immune systems in general and
related to mechanisms of FOXP3 expression speciﬁcally (nicely
reviewed by Ziegler in Ref.40)), and the development of skin
ﬁbrosis mimicking chronic GVHD in mice that survive the
acute phase of xGVHD.33 Here, we assessed the impact of AZA
on xGVHD and on graft-vs.-leukemia effects in NSG mice.
Main observations were that AZA mitigated GVHD through
multiple mechanisms including (1) anti-proliferative impact on
human T cells, (2) reduced pro-inﬂammatory environment
characterized by lower Th1 cytokines and lower expression of
each PERFORIN 1 (PRF1) and GRANZYME B (GZMB) by
cytotoxic T cells, and (3) promotion of highly suppressive Treg.
Treg promotion in AZA-treated animals was due to both
demethylation of FOXP3i1 and higher secretion of IL-2 by con-
ventional T cells (Tconv), subsequent to hypomethylation of
IL2 promoter site 1.
Results
Impact of AZA on human T cells in vitro
We ﬁrst investigated the impact of AZA on human T cells in
vitro. We observed that AZA signiﬁcantly reduced T-cell prolif-
eration on day 3, and the frequency of KI67C T cells on day 4
(92.9 vs. 82.6%, p D 0.0087) [Figs. 1A and B]. However, on day
8, frequencies of KI67C T cells were increased with AZA
(43.8 vs. 57.5%, p D 0.0448), while percentages of KI67C T cells
were low in the two conditions on day 12. Interestingly, treated
cells presented a higher activation status (assessed by the co-
expression of CD25 and HLA-DR) on days 8 and 12, while
MFI of CD25 was signiﬁcantly higher in AZA-treated than in
untreated cells throughout the experiment [Figs. 1C and D].
Altogether, these data suggest that AZA, while initially decreas-
ing T-cell proliferation, later induced an activation-promoting
effect.
Next, we assessed the impact of AZA on Treg differentiation
by using the same experimental setting. As previously reported
by other groups of investigators,25,26,30 we observed that AZA
dramatically increased the frequencies of CD25 and FOXP3
expressing cells among CD4C T cells [Fig. 1E]. To assess the
stability of these Tregs, we cultivated T cells without AZA, or
with AZA from day 0 to 4, or from day 0 to 8. Interestingly, we
observed that the Treg frequency slowly, but signiﬁcantly,
decreased after 4 and 8 d post-discontinuation of AZA (day
4 vs. 8: p D 0.065 and day 4 vs. 12: p D 0.026), although their
frequency remained higher than in untreated cells. In contrast,
cells treated with AZA during 8 d showed a stable Treg
frequency after AZA discontinuation.
Impact of AZA on xGVHD
To investigate the impact of AZA on xGVHD, NSG mice were
infused with huPBMC (20 £ 106 PBMC i.v.) on day 0 and were
then administered with PBS, or with 2 or 5 mg/kg of AZA every
48 h from day C1 to day C21 after transplantation. As shown
in Fig. 2A, survival was signiﬁcantly longer in mice receiving 2
or 5 mg/kg of AZA compared with control mice, while mice
treated with the 5 mg/kg dose beneﬁted from the best survival,
highlighting a dose-response effect (median survival: 100 d
(p < 0.0001) vs. 74 d (p D 0.04) vs. 44 d). In agreement with
survival data, xGVHD scores were also lower in AZA-treated
mice [Fig. 2B]. Similar observations were made in a second set
of experiment using the same experimental design with differ-
ent donors of PBMCs than in the ﬁrst experiment but with
AZA administered only at 5 mg/kg [Figs. 2C and D]. Histologi-
cal evaluations were performed on mice killed systematically
on day 28 (n D 10). These analyses demonstrated drastically
reduced histopathological score in lungs and liver (median
lung score 6.75 vs. 0 and median liver score 6.75 vs. 0) of AZA-
treated animals compared with controls [Fig. 2E and Table S1].
Further, anti-human CD3C staining in these organs conﬁrmed
strikingly less abundant inﬁltrates of human T cells in the
organs of AZA-treated mice. Similar observations were made
in the skin in a separate experiment [Fig. S1].
Impact of AZA on human PBMC engraftment
One possible mechanism by which AZA could delay xGVHD
development would be to reduce huPBMC engraftment. To
assess this hypothesis, immunophenotyping was performed on
PB on day 14, as well as on PB, SPL and BM on day 28. Surpris-
ingly, human PB chimerism levels were signiﬁcantly higher in
AZA-treated mice than in control animals on both days 14 and
28 [Table 1]. These apparently surprising results were due to a
greater deleterious impact of AZA on murine CD45C cells
count (because of myelotoxic effects, see Fig. S2) than on
human CD45C cells count [Table 1]. Interestingly, and while
AZA decreased human cells proliferation on day 4 (assessed by
CFSE dilution) and 14 (assessed by KI67 expression), the fre-
quency of huCD45
CKI67C in the spleen (SPL) on day 28 was
signiﬁcantly higher in AZA than in control mice [Fig. S3 and
Table 1]. This observation is consistent with our in vitro data
showing that AZA-treated cells presented a higher proliferation
than control cells at late time points.
In light of the deleterious impact of AZA on mouse CD45C
cell counts and on previous studies showing that AZA affected
human dendritic cells (DC),41 we investigated whether AZA
affected murine DC in our model. As showed in Figs. S4 and 5,
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ﬂow cytometry analysis showed that AZA reduced the fre-
quency of monocytes and DC while did not interfere with their
expression of CD86 and MHCII.
Immunomodulatory impact of AZA
To further determine the mechanisms of xGVHD prevention
by AZA, immunophenotyping by ﬂow cytometry was per-
formed on day 28 on SPLs from transplanted mice and given
or not AZA (5 mg/kg s.c.). To avoid inter-donor variability,
this experiment was conducted three times (with three different
donors) and only results conﬁrmed in the three experiments
were considered as signiﬁcant (results from the ﬁrst experiment
are shown hereafter as representative example).
In light of the proliferation differences of huCD45
C cells
between control and treated mice on day 28, we examined
whether the activation state of human T cells was affected by
AZA. CD4C and CD8C were assayed for their expression of
HLA-DR and CD25. Supporting our observation of an activa-
tion-promoting effect in vitro, a signiﬁcantly higher propor-
tion of cells co-expressing HLA-DR and CD25 was observed
both in CD4C and CD8C T cell subsets from AZA-treated
than control mice [Table 1]. Further, the proportions of
CD4CIL-2C T cells as well as IL2 mRNA levels in splenocytes
and serum IL-2 concentration were higher in AZA-treated
mice. These data support the hypothesis that AZA promotes
T-cell activation.
We next investigated the impact of AZA on speciﬁc mole-
cules of helper and cytotoxic T cells. We observed a reduced
frequency of IFNgC CD4C T cells, a lower expression of IFNG
mRNA as well as a diminished expression of TBET mRNA in
AZA-treated mice [Table 1]. Furthermore, serum IFNg and
TNF-a concentrations were also signiﬁcantly lower in AZA
than in control mice. Interestingly, while GATA3 mRNA
expression was also decreased, suggesting decreased Th2-cell
frequency, IL-17 as well as RORC mRNA expressions were
comparable between control and treated mice.
GZMB secretion by CD8C T cells has been shown to have a
pivotal function in GVHD as GZMB deﬁciency was found to
alleviate cytotoxic T-cell-mediated GVHD in mouse-to-mouse
models of GVHD.42 Therefore, we assessed whether AZA could
impact the expression of GZMB and PRF1 by CD8C T cells and
we observed lower frequencies of GZMB- and PRF1-secreting
CD8C T cells in mice given AZA compared with control ani-
mals [Table 1].
Altogether, these data suggest that GVHD prevention by
AZA might also involve an immunomodulatory effect on both
effector CD4C and CD8C T cells.
Impact of AZA on Treg
To assess the impact of AZA on Treg in vivo, we measured
FOXP3 mRNA levels by RT-qPCR and proportions of
CD4CCD25CFOXP3C cells by ﬂow cytometry on day 28 in SPL
and/or PB of transplanted mice given or not AZA (5 mg/kg).
As hypothesized, FOXP3 mRNA levels were increased 2- to 4-
folds in AZA-treated mice [Fig. 3A]. Accordingly, frequencies
of CD4CCD25CFOXP3C T cells in PB and SPL of AZA-treated
mice were signiﬁcantly higher than in control mice [Figs. 3B
and C]. Importantly, we also measured the proportions of cells
with a demethylated FOXP3i1 region in the SPLs of control
and AZA mice on day 28 and observed signiﬁcantly higher pro-
portions of these cells in AZA-treated than in control mice
[Fig. 3D].
Figure 1. AZA reduces proliferation but increases activation of T cells and increases Treg frequency in vitro. Fresh T cells from three healthy volunteers were incubated for
12 d in technical duplicates in the presence or not of 1 mM of AZA. (A) CFSE loaded T cells were incubated for 3 d in presence of AZA (bold) or PBS (dashed) and analyzed
by ﬂow cytometry (FCM). (B–D) FCM comparisons of KI67C (B), CD25CHLA-DRC (C) and CD25 MFI (D) of T cells on days C4, C8, C12 in presence or not of AZA (given
from day 0 to day 8). (E) Evolution of CD4CCD25CFOXP3C Treg cells frequency among cultured CD4C T cells receiving AZA for 4 d (red), 8 d (green) or PBS for 8 d (blue)
on days C4, C8, C12, analyzed by FCM (p-values report the comparison of each time point with day C4 from the corresponding condition). Data show median values of
biologic triplicates and technical duplicates (n D 6) with interquartile range (p < 0.05, p < 0.005, p < 0.0005).
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To investigate whether the increased Treg frequency in AZA
mice originates only from the hypomethylating effect of the
drug or also from a promotion of Treg over Tconv prolifera-
tion, we compared the frequency of KI67C Tconv and Treg in
control and AZA-treated mice. As shown in Fig. 3E, while the
frequencies of KI67CTconv and KI67CTreg were both signiﬁ-
cantly higher in AZA-treated than in control mice, the KI67C
Treg:KI67CTconv ratio was also signiﬁcantly higher in
AZA-treated mice [Fig. 3F]. Since Treg proliferation is medi-
ated mainly by signaling through the STAT5 pathway after IL-
2 binding to its receptor,43 we investigated the STAT5
phosphorylation level in both Treg and Tconv, as described
previously.44 In agreement with the higher secretion of IL-2
observed in AZA-treated mice, we observed signiﬁcantly higher
STAT5 phosphorylation levels in Tconv and Treg populations
in AZA-treated mice, and to a greater extent in the latter
[Figs. 3G and H]. Because the demethylation of a unique site
(site 1) in the IL2 promoter is essential for inducing IL2 expres-
sion and because AZA has been reported to induce IL2 expres-
sion through hypomethylation of this region,45 we investigated
the methylation status of this region in genomic DNA extracted
from splenocytes of one mouse from each condition. We found
that 73.6% vs. 15.7% of sequences were demethylated in
AZA-treated vs. control mice. Altogether, these data suggest
that AZA mediates Treg proliferation through the promotion
of IL-2 secretion by Tconv subsequent to IL2 gene promoter
site 1 demethylation.
To determine the suppressive ability of Treg from AZA-
treated mice, we sorted CD4CCD25CCD127low T cells (Treg)
and CD4CCD25¡ T cells (Tconvs) from SPL of control and
AZA-treated mice killed at day 28. Then, the capacity of Treg
to inhibit CD3/CD28-triggered proliferation of CFSE loaded
Tconvs was assessed. As shown in Figs. 4A and B, Treg sorted
from AZA-treated mice presented a similar or higher
Figure 2. AZA mitigates xGVHD. NSG mice were injected with 2 £ 107 human PBMC i.v. and received or not AZA subcutaneously every 48 h at doses of either 2 or 5 mg/
kg starting on day C1 until day C21. (A, B) Survival and GVHD scoring curves of two groups of mice transplanted with two different healthy donors (n D 12/donor)
receiving PBS, 2 or 5 mg/kg of AZA (n D 8/condition). (C, D) Pooled survival and scoring curves of two groups of mice transplanted with two different healthy donors
(n D 9–10/donor) receiving PBS or 5 mg/kg of AZA (n D 9–10/condition). Mice that reached a score of 6 were estimated to have terminal GVHD and were killed. Final
score for dead animals reaching the ethical limit score were kept in the data set for the remaining time points (last observation carried forward). (E) Histological evaluation
of tissue lesions (hematoxylin and eosin) and human CD3C inﬁltrates in liver and lungs was performed at day 28 post-transplantation. In the control group, lymphoid inﬁl-
trates and endotheliitis were observed in the lungs, and portal tract expansion, endotheliitis and parenchymal alterations were observed in the liver (hematoxylin and
eosin). In treated mice, both lungs and liver showed only focal inﬁltrates and overall subnormal histology. Immunostainings with anti-human-CD3 showed a dense inﬁl-
trate of donor lymphocytes in both organs in control animals while a very low burden of inﬁltrate was observed in treated mice.
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suppressive ability than Treg from control animals. In accor-
dance with these data and in addition to the greater FOXP3
expression and pSTAT5 signaling, a higher expression of HLA-
DR, ICOS and IL-35 as well as a diminished expression of
GITR were observed in AZA-treated mice [Supplemental
Results, Fig. S6 and Table S2].
Finally, we assessed the long-term stability of AZA-induced
Treg by measuring their frequency in blood of mice included in
the second survival curve 60 d post-transplantation. This analy-
sis showed that 3 out of 8 treated mice (all control mice had
succumbed before day 60) still presented a Treg frequency in
the range observed at day 28 (5–10% of CD4C T cells). Interest-
ingly, we noticed that on day 60 several mice started or had
developed chronic GVHD symptoms (i.e., hair loss and skin
ﬁbrosis). Therefore, we classiﬁed these eight remaining mice in
three groups according to chronic GVHD symptoms: no signs
of chronic GVHD, mild signs of GVHD (rufﬂed fur), or severe
signs of chronic GVHD (hair loss and skin sclerosis) and com-
pared the Treg frequency between the three groups. Interest-
ingly, we observed that the mice presenting the highest Treg
frequency remained free of chronic GVHD symptoms
[Figs. 5A and B]. In contrast, mice with signs of chronic
GVHD had either very few or no Treg in their blood on day 60.
Altogether, these data suggest that AZA is capable of inducing
or promoting long-living Treg, although this was not observed
in all treated mice. Further, our data suggest also that Treg
persistence might be associated with protection from chronic
GVHD.
AZA promotes long-term tolerance
To determine the impact of AZA on long-term tolerance, NSG
mice, irradiated with 2.5 Gy on day ¡1, received a secondary
transplant with 4 £ 106 human cells obtained from the SPL of
control or AZA-treated mice, killed at day 28. AZA was not
administered after second transplantation. As shown in
Fig. 6A, all mice given human cells from AZA mice survived
beyond day 100, while all mice given human cells from control
mice died of GVHD within 40 d. Further, in comparison to
mice given human cells from control mice, those given cells
from AZA mice had signiﬁcantly lower GVHD clinical scores
and much higher Treg frequencies, demonstrating that Treg
induced by AZA were stable and kept mostly a Treg phenotype
[Figs. 6B and C].
We next examined the implication of Treg in this long-term
tolerance by depleting CD25C cells from human CD45C cells
before secondary transplant. In agreement with previous
reports,46 we found that the depletion of CD25C cells from the
secondary graft increased xGVHD lethality in comparison with
the undepleted group, demonstrating that Treg play a protec-
tive role in this setting. In line with this observation, a signiﬁ-
cant reduction of survival was also observed in mice
Table 1. Impact of AZA on engraftment, proliferation and immunomodulation. NSG mice were transplanted with 2 £ 107 human PBMC, treated or not with AZA, and
FACS was performed on blood cells on day 14 or FACS and RT-qPCR were performed on spleen, blood and bone marrow cells on day 28 after sacriﬁce. Human chimerism
was calculated as the ratio of human CD45C cells (huCD45C) vs. murineChuman CD45C cells. CFSE dilution of huCD45C cells was analyzed in spleen, 4 d after transplanta-
tion of 4 mice/condition with 2 £ 107 CFSE-loaded human PBMCs. Blood absolute counts were calculated based on white blood cell count performed with hematological
cell counter (Sysmex) and hu/muCD45
C cell frequency determined by FACS. Transcript levels measured by RT-qPCR were normalized on human housekeeping gene (TBP).
Data show median values of 8–10 mice/condition with interquartile range (IQR).
CTRL AZA
Parameter Method Median IQR Median IQR p-value
Human chimerism (%): FACS
Day 14, peripheral blood 10.3 8.86–12.94 26.91 22.84–37.84 0.0007
Day 28, peripheral blood 60.09 51.72–70.25 90.94 66.95–93.49 0.014
Day 28, spleen 83.09 78.73–87.33 66.5 57.50–83.67 0.1893
Day 28, bone marrow 3.25 1.05–9.09 10.04 8.32–18.79 0.041
KI67C among huCD45C (%): FACS
Day 14, peripheral blood 38.15 33.20–47.38 20.3 14.65–24.80 < 0.0001
Day 28, spleen 20.8 14.28–24.35 43.9 36.20–48.45 < 0.0001
CFSEdim among huCD45
C (%): FACS
Day 4, spleen 69 64.30–75.80 48.6 46–50.4 0.0039
Blood absolute count (103/mL): Sysmex and FACS
Day 14, huCD45
C 0.127 0.093–0.199 0.056 0.047–0.082 0.0093
Day 14, muCD45
C 0.168 0.131–0.359 0.051 0.037–0.11 0.0012
Sacriﬁce day 28, spleen:
% CD4CCD25CHLA-DRC T cells FACS 1.935 1.52–4.218 12.4 8.47–14.15 < 0.0001
% CD8CCD25CHLA-DRC T cells 3.095 2.683–3.67 4.88 4.03–7.125 0.017
% IL-2C among CD4C T cells 7.86 7.33–10.90 22.6 19.40–26.60 0.0003
IL2 relative expression RT-qPCR 0.574 0.355–0.842 1.35 1.22–1.56 0.0002
% IFNgC among CD4C T cells FACS 67.4 66.90–73.50 60.5 57.40–65.50 0.0079
IFNG relative expression RT-qPCR 1.281 0.944–1.7 0.36 0.213–0.777 0.0021
TBET relative expression 1.82 1.578–2.315 0.689 0.58–0.891 < 0.0001
GATA3 relative expression 1.515 1.3–1.935 0.819 0.623–1.29 0.0025
% IL-17C among CD4C T cells FACS 1.81 1.74–3.01 2.02 1.855–2.37 0.873
RORC relative expression RT-qPCR 1.403 1.107–2.111 2.111 1.384–3.685 0.1903
% GZMBC among CD8C T cells FACS 70.85 68.63–78.55 46.7 43.1–55.6 0.0003
% PRF1C among CD8C T cells 69 63.23–76.25 47.2 39.6–51.4 0.0006
Serum cytokine day 28 (pg/mL)
IFNg Bio-Plex 1554 1,450–2,348 31.25 23.46–78.80 0.0002
TNF-a 47.33 20.24–61.47 5.03 2.27–5.48 0.0002
IL-2 1.76 1.32–3.43 3.11 2.29–3.61 0.1304
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transplanted with CD25C-depleted cells from AZA-treated
mice, in comparison with mice receiving total CD45C cells
[Fig. 6D]. However, and surprisingly, the Treg frequency at day
14 was not signiﬁcantly different between CD25-depleted and
total CD45C groups in the AZA condition, while it was reduced
in CD25-depleted group in control condition [Fig. 6E]. Alto-
gether, these data indicate that AZA-generated Tregs play a
protective role in xGVHD and favor long-term tolerance and
that AZA-induced genomic hypomethylations preserve a long-
term Treg-promoting effect, even when Treg were depleted
from the secondary graft.
AZA impact on graft-vs.-leukemia effect
We next investigated whether the immunomodulatory effects
of AZA impacted graft-vs.-leukemia effect. Using THP-1 leuke-
mia cells (a cell line sensitive to AZA47), transfected to express
luciferase, we evaluated the elimination of leukemia cells after
transplantation of NSG mice with PBMCs in combination or
not with AZA administration, by in vivo bioluminescent imag-
ing. Better survival rates were found in mice receiving AZA
treatments (reﬂecting the inhibition of THP-1 growth by AZA
on the one hand and xGVHD prevention by AZA on the other
hand), regardless of PBMC administration, while all mice
receiving PBMCs without AZA died from GVHD and mice
receiving THP-1 cells without AZA or PBMC died from leuke-
mia [Fig. 7A]. Accordingly, at day 28, tumors were observed
only in mice having received THP-1 cells alone [Fig. 7B]. At
day 49, we observed a relapse of leukemia in
mice treated with AZA alone while no tumors were found in
mice receiving PBMCsCAZA, demonstrating that AZA does
not abrogate the capacity of immune cells to clear tumor cells
(graft-vs.-leukemia effects) and that the anti-leukemic effects of
AZA were not sustained after AZA discontinuation. Speciﬁ-
cally, 6/6 mice transplanted with THP-1 cells and treated with
AZA without PBMC infusion presented important tumor bur-
den in BLI examination within the last 7 d before their sacriﬁce
for terminal AML and 7/7 mice having received THP-1 C
PBMCs C AZA presented no signs of tumors before sacriﬁce
for terminal chronic GVHD or at the end of the experiment
[Fig. S7A]. Further, PBMCs C AZA mice had signiﬁcantly bet-
ter survival than AZA mice (86 vs. 114 days, p D 0.047)
[Fig. 7A]. To assess whether PBMCs injected in mice having
received THP-1CPBMCsCAZA were still capable to mediate
Figure 3. AZA increases Treg frequency and IL-2-mediated proliferation. Spleen from NSG mice transplanted with 2 £ 107 human PBMC and receiving or not AZA 5 mg/
kg every 48 h from day C1 to C21 were harvested on day 28 and were homogenized for either ﬂow cytometry or PCR analyses. (A) RT-qPCR comparison of FOXP3 tran-
script level, normalized on human housekeeping gene (TBP). (B, C) FACS comparison of CD25CFOXP3C (in spleen and blood) and CD25CCD127lowFOXP3C (in spleen) cell
frequency within the CD4C T cell population. (D) MS-qPCR assessment of demethylated FOXP3 intron 1 sequences performed on genomic DNA extracted from spleen
homogenate of mice treated or not with AZA. (E) FACS comparison of KI67C cell frequency within regulatory (Treg: CD4CCD25CFOXP3C, in blue) and conventional T cell
(Tconv: CD4CFOXP3¡, in red) populations. (F) Comparison of ratio, for each mouse treated or not with AZA, of KI67CTreg frequency vs. KI67C Tconv frequency, based on
frequencies found in Fig. 3E. (G) FACS comparison of phosphorylated-STAT5 mean ﬂuorescence intensity (MFI) between Treg (in blue) and Tconv (in red) in spleen. (H)
Comparison of ratio, for each mouse treated or not with AZA, of pSTAT5 MFI of Treg vs. pSTAT5 MFI of Tconv, based on MFI’s found in Fig. 3G. Data show median values
of 8–10 mice/condition with interquartile range (p < 0.05, p < 0.005, p < 0.0005).
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graft-vs.-leukemia effect at the end of experiment (day 130), we
transplanted these mice, together with untreated age-matched
NSG mice (n D 3), with 1 £ 106 THP-1-luc cells in matrigel.
BLI showed that tumor progression was either inhibited or
decreased in PBMCsCAZA mice while a rapid progression was
observed in control animals [Fig. S7B]. This clearly indicates
that T cells from AZA-treated mice kept the possibility to
mediate graft-vs.-leukemia effects a long time after AZA
discontinuation.
To conﬁrm these results and better mimic the clinical setting
of allo-HSCT (in which the GVHD and graft-vs.-leukemia
reactions are often directed toward similar antigens), we
assessed the impact of AZA on xGVHD and graft-vs.-leukemia
effects in NSG mice expressing the human HLA-A0201 antigen
(NSG-HLA-A2/HHD), which is also expressed by THP-1 cells.
First, we assessed whether AZA ameliorated xGVHD in that
model and observed that indeed AZA decreased xGVHD also
in NSG-HLA-A2/HHD mice injected with human PBMC
(from a human donor non HLA-A2) [Figs. 8A and B]. Then,
we repeated the experiment performed in Fig. 7 (by using iden-
tical experimental design) and found that NSG-HLA-A2/HHD
given the combination of AZA and PBMCs presented a
reduced tumor burden and signiﬁcantly higher survival rates
than mice given AZA only [Figs. 8C and D]. While tumors
were not eradicated by AZA in this experiment, these data are
in agreement with observations done in the classical NSG mice,
showing that AZA maintained at least partly the graft-vs.-leu-
kemia activity of T cells.
Given that NK cells were previously reported to play an
important role in GVL effects,48,49 we sought to investigate
whether these cells played a signiﬁcant role in THP-1 cells
elimination in NSG mice injected with human PBMCs and
whether AZA may have an impact on these cells in this set-
ting. We ﬁrst investigated the susceptibility of THP-1 cells
Figure 5. Absence of « chronic » GVHD development in AZA-treated mice is associated with high Treg frequency. NSG mice transplanted with 2 £ 107 human PBMC and
receiving or not AZA 5 mg/kg were monitored for survival and GVHD score (Figs. 2C and D). On day 60 post-transplantation, blood was harvested from surviving mice
(only AZA-treated animals) and ﬂow cytometry was performed to evaluate Treg frequency. (A) Mice were segregated in three groups according to « chronic » GVHD symp-
toms and Treg frequency was compared between the groups. (B) Frequency of Treg in each mouse of the three groups.
Figure 4. AZA promotes Treg suppressive activity. (A, B) Representative histograms (A) and comparative panels (B) of the suppression of CD4CCD25CCD127low Treg
sorted from spleen of transplanted NSG mice, treated or not with AZA 5 mg/kg, on day 28. Treg were added to autologous CD3/CD28-stimulated Tconvs at a ratio of
either 1:1, 1:4 or 1:16 (Treg:Tconv) and proliferation was measured by CFSE dilution, in triplicates. Dotted curve: Tconv alone; tinted curve: TconvCTreg. Data show mean
values of three wells/condition with SEM.
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to NK cells-mediated lysis by performing cytotoxicity and
degranulation assays with the NK92 cell line. We found
that THP-1 cells were poorly susceptible to cell lysis com-
pared with the K562 cell line (used as positive control of
NK cytotoxicity) [Fig. S8A]. Next, we assessed whether
AZA treatment of THP-1 cells could impact the capacity of
NK cells to mediate their lysis and found no signiﬁcant
effect of AZA [Fig. S8B]. Finally, we treated the NK92 cells
with AZA or not and assessed their cytotoxicity toward
K562 [Fig. S8C] and THP-1 [Fig. S8D] cells and found no
signiﬁcant impact of AZA on their lysis capacity. Finally,
and while NK cells poorly engraft in PBMCs-infused NSG
mice,34,46 we evaluated the impact of AZA on the expres-
sion of three NK cell genes: KLRC4 (encoding NKG2D),
NCR1 (encoding NKp46) and NCR3 (encoding NKp30) in
SPLs of mice, treated or not with AZA, at day 28. As
showed in Fig. S9, the expression of KLRC4 and NCR1
were decreased by AZA, while the expression of NCR3 was
unchanged, suggesting that AZA decreased the engraftment
of NK cells. Altogether, these results suggest that NK cells
probably play a minor role in GVL effects against THP-1
cells in AZA-treated NSG mice.
Finally, we examined the impact of AZA on graft-vs.-leuke-
mia effect independently of leukemia cells exposure to AZA.
NSG mice, transplanted with PBMCs and treated or not with
AZA, were killed at day 28 and human CD45C cells were sorted
from their SPL. Then, 4 £ 106 of these cells were injected to
irradiated NSG mice, co-injected with THP-1-luc cells
[Fig. S10A]. AZA was not administered after this second trans-
plantation. Survival and in vivo luciferase bioluminescence
were monitored during the experiment. As showed in
Figs. S10B and C, no signiﬁcant difference of either survival or
bioluminescence were found between mice receiving THP-1
alone or THP-1 in combination with AZA-conditioned human
CD45C cells. Altogether, these results highlight the important
tolerogenic effects of AZA in secondary transplant experiment
but may indicate, at least in part, a deleterious impact of AZA
on graft-vs.-leukemia effect in that artiﬁcial transplantation
setting.
Discussion
Hypomethylating agents, such as AZA, are highly active against
acute myeloid leukemia or myelodysplastic cells,20 and, in addi-
tion, prevented GVHD by favoring FOXP3 demethylation and
the generation of Treg in mouse-to-mouse models of
GVHD.25,26 In the present report, we investigated the impact of
AZA on xGVHD in a humanized mouse model of GVHD in
which xGVHD is induced by transplanting human PBMC in
NSG mice.12,13,35 This model tackles several important limita-
tions of mouse to mouse models of GVHD since it allows (1) a
genetic diversity of effector cells (this is a crucial point for
studying agents with a wide demethylating activity), (2) the use
of human cells to induce (and control) GVHD (this is particu-
larly relevant in this study given the important difference of
FOXP3 regulation in mice and humans40), (3) the use of effec-
tors immune cells from adults that have been previously
exposed to pathogens, (4) to induce GVHD without the need
of intense conditioning regimen and (5) the development of
chronic GVHD in mice that survive the acute phase of the dis-
ease (as observed in humans). Previous studies using that
model demonstrated that blockade of TNF-a,34,46 blockade of
Figure 6. AZA induces long-term tolerance. Spleen from NSG mice transplanted with 2 £ 107 human PBMC and receiving or not AZA 5 mg/kg were harvested on day 28,
were homogenized and pooled (CTRL with CTRL and AZA with AZA). Spleen homogenates were either infused per se to 2.5Gy-irradiated NSG mice (4 £ 106 huCD45C
cells/mouse), or were depleted of human CD25C cells before infusion (4 £ 106 huCD45C cells/mouse). (A, B) Survival and GVHD scoring curves (n D 6/condition) of mice
transplanted with total spleen homogenates. (C) FACS comparison of CD25CFOXP3C cell frequency within the CD4C T cell population in blood at 14 and 40 d post-trans-
plantation. (D) Survival curve (n D 6–7/condition) of mice transplanted with either total or CD25C-depleted spleen homogenates. (E) FACS comparison of CD25CFOXP3C
cell frequency within the CD4C T cell population in blood at 14 d post-transplantation. Data show median values of 6–7 mice/condition with interquartile range (p <
0.05, p < 0.005, p < 0.0005).
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T-cell proliferation,46 JAK2 and aurora kinase 2 inhibition,50 as
well as administration of Treg12,13,35 each prevented or amelio-
rated xGVHD. In the current study, we ﬁrst demonstrated that
AZA mitigated GVHD and promoted long-term tolerance.
Further, we identiﬁed several mechanisms probably explaining
these ﬁndings: (1) partial inhibition of human T-cell prolifera-
tion by AZA, (2) partial inhibition of Th1 differentiation by
AZA, (3) reduced expression of cytotoxic effector molecules by
CD8C T cells in AZA mice, and last but not least (4) Treg
promotion by AZA. In addition, and most importantly, we
demonstrated that AZA did not abrogate graft-vs.-leukemia
effects.
A phase II clinical study of AZA administration after
alemtuzumab-based reduced-intensity allo-HCT has suggested
that AZA might decrease the incidence of acute GVHD
through Treg promotion.27 However, patients included in that
study also received 50 mg of alemtuzumab in the conditioning
regimen (which is associated with a very low incidence of
Figure 7. AZA treatment maintains graft-vs.-leukemia effect. NSG mice were transplanted with 2 £ 107 human PBMC together or not with 3 £ 106 THP-1-luc cells. Mice
were either treated or not with AZA 5 mg/kg and survival (A) and bioluminescence (B) were monitored. Actual images of one representative mouse from each group
are shown with Y-axis indicating photon ﬂux (photons/sec) measured from the ventral view with a region of interest drawn over the entire body of each mouse. Right
panels show the comparison of bioluminescence between groups. Data show median values of 6–7 mice/condition with interquartile range (p < 0.05, p < 0.005,
p < 0.0005).
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cGVHD by itself51), making difﬁcult to draw deﬁnitive conclu-
sions on the impact of AZA on GVHD in humans. Treg induc-
tion by AZA in that phase II study was not durable,
perhaps due to the schedule of AZA administration or to the
concomitant use of cyclosporine. A ﬁrst important observation
of the present study was thus that AZA prevented GVHD in a
humanized mouse model. The impact of AZA was impressive
with very signiﬁcantly higher survival and lower clinical and
pathological xGVHD scores among AZA-treated mice. These
data are in line with previous observations made in mouse-
to-mouse models of GVHD.25,26,31
A ﬁrst mechanism possibly explaining xGVHD protection
by AZA might be an AZA-induced T-cell proliferation inhibi-
tion. Indeed, we observed signiﬁcant lower counts of huCD45
C
cells on day 14 after transplantation, suggesting an anti-prolif-
erative impact of AZA, that was further conﬁrmed by in vivo
and in vitro CFSE dilution experiments and KI67 expression.
AZA has also been previously shown to reduce T-cell activa-
tion in vitro after 48 h of culture but not at later time points
when AZA was found to increase T-cell activation.25,30,52 In
line with these ﬁndings, we observed that AZA had a pro-acti-
vation activity both in vitro after 8 d of culture and in vivo on
day 28 after huPBMC injection (7 d after last AZA administra-
tion). Interestingly, this higher activation status of T cells in
treated mice was not characterized by a pro-inﬂammatory envi-
ronment but rather by decreased Th1 differentiation, decreased
expression of cytotoxic effector molecules (PRF1 and GZMB)
and reduced serum level of proinﬂammatory cytokines such as
IFNg and TNF-a. Furthermore, we found that AZA did not
affect Th17 cells while dramatically increasing Treg frequency,
therefore increasing the Treg/Th17 ratio that has been shown
to correlate with GVHD improvement.53
As hypothesized, we observed higher Treg frequencies in
AZA-treated mice. Interestingly, our data suggest that the cause
of this increased Treg frequency was probably multifactorial.
Indeed, while a higher frequency of cells with a demethylated
FOXP3i1 was observed in AZA mice (suggesting conversion of
Tconv into Treg), we also demonstrated higher Treg prolifera-
tion in AZA-treated mice together with higher levels of pSTAT5.
Given the thigh link between IL-2 and Treg STAT5-dependent
proliferation/survival,54-57 these observations suggest higher
IL-2 levels in AZA-treated mice. Accordingly, we could demon-
strate that AZA-treated mice presented a higher secretion of
IL-2 by helper T cells than control animals, concomitant with a
higher demethylation status of IL2 gene promoter. This later
observation is consistent with previous reports demonstrating
that IL2 gene expression is upregulated by its promoter hypome-
thylation and that AZA promotes IL-2 secretion.31,45,58,59
Importantly, we observed that Treg sorted from AZA-treated
mice presented a higher suppressive activity in MLR than Treg
from control mice perhaps as a result of higher STAT5
phosphorylation level (highlighting higher IL-2 signaling), and a
higher expression of both HLA-DR and ICOS, two markers of
activation expressed by highly suppressive Treg.60,61
Figure 8. AZA treatment maintains graft-vs.-leukemia effect in NSG-HLA-A2/HHD mice. (A, B) NSG-HLA-A2/HHD mice were transplanted with 2 £ 107 human PBMC i.v.
and were treated or not with AZA subcutaneously every 48 h at doses of 5 mg/kg starting on day C1 until day C21. Survival (A) and xGVHD scores (B) were monitored
(n D 5–6 / condition). (C, D) NSG-HLA-A2/HHD mice were transplanted with 3 £ 106 THP-1-luc cells together or not with 2 £ 107 human PBMC. Mice were either treated
or not with AZA 5 mg/kg and survival (C) and bioluminescence (D) were monitored. Actual images of one representative mouse from each group are shown with Y-axis
indicating photon ﬂux (photons/sec) measured from the ventral view with a region of interest drawn over the entire body of each mouse. Right panels show the compar-
ison of bioluminescence between groups. Data show median values with interquartile range (p < 0.05, p < 0.005, p < 0.0005).
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Very few data are currently available about the long-term
stability of AZA-induced Treg. In the present report, we
observed that AZA-induced Treg frequency slowly decreased
after AZA discontinuation in vitro, in accordance with previ-
ously published data in allo-HCT recipients.27 However, Treg
levels remained stable in 3 out of 8 mice more than 30 d after
discontinuation of AZA administration. Further, and interest-
ingly, in contrast to the ﬁve remaining mice that lost the major-
ity, or all, human Treg, the three mice with high Treg levels
remained free of chronic GVHD. We also observed the persis-
tence of a high frequency of Treg (and a protection from
xGVHD) in secondary transplant performed with huPBMC
harvested from the SPLs of AZA-treated mice. Further, the
depletion of Tregs before secondary transplantation highlighted
that Treg play a protective role from GVHD in that model
as previously demonstrated. Interestingly, their high frequency
in animals receiving Treg-depleted CD45C cells from
AZA-treated animals suggested that AZA induced long-term
hypomethylation signature promoting Treg differentiation.
Finally and most importantly, we investigated the impact of
AZA on graft-vs.-leukemia effects. Indeed, while several
approaches allowed separating graft-vs.-leukemia effects from
GVHD in mouse-to-mouse models of GVHD, very few of
them have been successfully translated in the clinic. Although
prophylactic AZA administration has been studied in phase II
studies after allo-HCT, its net impact on graft-vs.-leukemia
effects in humans has remained unsolved. On the one hand,
AZA induces the expression of tumor antigens by AML cells
leading to the generation of donor-derived tumor-speciﬁc cyto-
toxic T cells that have been shown to protect from AML
relapse.27,62 On the other hand, the tolerogenic effects of AZA
might predict a negative impact of AZA on graft-vs.-leukemia
effects given the well-known link between GVHD and graft-
vs.-leukemia effects in humans.1,63,64 In support of this hypoth-
esis, post-transplant AZA administration was associated with a
higher proportion of patients with persistent mixed chimerism
in the study by Goodyear et al.27 In the current study, using an
AZA-sensitive AML cell line, we observed that the best survival
was achieved in mice treated with AZA and human PBMC, this
approach allowing efﬁcient GVHD prevention by AZA without
(the complete) loss of the graft-vs.-leukemia effects induced by
human PBMC. However, we found a complete abrogation of
graft-vs.-leukemia effects in secondary transplants as mice
transplanted with AZA-conditioned CD45C cells failed to elim-
inate tumor cells. In light of the almost complete absence of
GVHD and the very high Treg frequencies in these mice, we
assume that this absence of graft-vs.-leukemia effects reﬂect the
very high tolerogenic impact of AZA in that transplantation
setting.
In conclusion, our ﬁndings indicate that AZA might be a
promising option for separating GVHD from graft-vs.-leuke-
mia effects in humans in patients with AZA-sensitive leukemic
cells.
Material and methods
All experimental procedures and protocols used in this investi-
gation were reviewed and approved by the Institutional Animal
Care and Use Committee of the University of Liege,
Belgium. The “Guide for the Care and Use of Laboratory Ani-
mals,” prepared by the Institute of Laboratory Animal Resour-
ces, National Research Council, and published by the National
Academy Press, was followed carefully as well as European and
local legislation. Animal welfare was assessed at least once per
day with humane endpoints applied when necessary as
described in the ethical form.
Induction of xenogeneic GVHD in NSG mice and AZA
administration
NOD-scid IL-2Rgnull (NSG) mice (The Jackson laboratory, Bar
Harbor, ME) and NSG mice expressing the HHD construct
designed for the expression of human HLA-A0201 covalently
bound to human b2 microglobuline (NSG-HLA-A2/HHD)
mice65 (The Jackson laboratory), aged from 8 to 10 weeks, were
given an i.v. injection of 2 £ 107 huPBMC (obtained from buffy
coats from healthy volunteers) to induce xGVHD. GVHD
severity was assessed by a scoring system that incorporates four
clinical parameters: weight loss, posture (hunching), mobility
and anemia. Each parameter received a score of 0 (minimum)
to 2 (maximum). Mice were assessed for GVHD score thrice
weekly and monitored daily during the experiments. Mice
reaching a GVHD score of 6/8 or losing 20% of body weight
were euthanized in agreement with the recommendation of our
ethical committee. Final scores for dead animals reaching the
ethical limit score were kept in the data set for the remaining
time points (last value carried forward). AZA (Sigma Aldrich),
dissolved and diluted in sterile PBS, was administered subcuta-
neously every 48 h at doses of either 2 or 5 mg/kg starting on
day C1 until day C21.
Flow cytometry
At the time of necropsy, peripheral blood (PB), SPL and bone
marrow (BM) were harvested and analyzed by ﬂow cytometry.
Splenocytes were obtained by crushing the SPL, and BM cells by
ﬂushing femurs and tibiae. Cells were counted with a Sysmex
XS-800i. PB was depleted of erythrocytes using RBC lysis
buffer (eBioscience, San-Diego, CA) according to manufac-
turer’s instructions. The following antibodies speciﬁc for human
antigens were used: anti-CD3-V500 (SP34–2, BD); anti-CD4-
eﬂuor 450 (RPA-T4); anti-CD4-PerCP (SK3, BD); anti-CD8-
FITC (HIT8a); anti-CD8-APC-Cy7 (SK1, BD); anti-CD45-
PerCP (2D1, BD); anti-CD45-BV510 (HI30, BD); anti-CD45-
PE-Cy7 (HI30); anti-CD25-BV421 (M-A251, BD); anti-CD25-
PE-Cy7 (BC96); anti-CD127-biotin (RDR5); anti-HLA-DR-
APC-eﬂuor780 (LN3), anti-GITR-APC (eBioAITR), anti-ICOS-
APC (ISA-3), anti-FOXP3-AlexaFluor488 (206D and 259D,
Biolegend, San-Diego, CA), anti-KI67-APC (B56, BD), anti-
CTLA-4-PE (14D3), anti-phosphoSTAT5-APC (pY694, BD),
anti-GRANZYME B-PE (GB11, BD), anti-PERFORIN-1-
PerCP-Cy5.5 (dG9, BD), anti-IL-2-V450 (MQ1–17H12), anti-
IL10-PE (JES3–9D7), anti-IL-17-APC (eBio64DEC17), anti-
IFNg-PE-Cy7 (4S.B3) and the following antibodies speciﬁc for
mouse antigens were used: anti-CD45-PerCP-Cy5.5 (30-F11),
CD11b-APC (M1/70), Ly-6G-FITC (RB6–8C5), CD11c-
eFluor450 (N418), CD86-biotin (GL1) and MHCII-PE (M5/
114.15.2) (all eBioscience unless indicated otherwise). Cells
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(1.5–2£ 106 cells/sample) were incubated with surface antibod-
ies for 20 min at 4C in the dark and washed twice with PBS/3%
FBS (Lonza). Intracellular staining for FOXP3 (206D), KI67,
CTLA-4, PRF1, GZMB and cytokines was performed by using
the Transcription Factor Buffer Set (Becton-Dickinson, Bedford,
MA). For pSTAT5 and FOXP3 (259D) staining, the PerFix
EXPOSE reagent kit (Beckman Coulter, Fullerton, CA) was used
as previously reported.44 For intracellular cytokine staining, SPL
homogenates were stimulated for 6 h in RPMI supplemented
with 10% FBS, penicillin (100 U/mL), streptomycin (10 mg/mL)
and in presence of PMA/ionomycin, brefeldin A and monensin
(Cell Stimulation CocktailC Protein Transport Inhibitors, eBio-
science). Data were acquired on a FACS Canto II ﬂow cytometer
(Becton Dickinson) and analyzed with the Flowjo software 7.0
(Tree Star Inc., Ashland, OR).
Methods for cell culture, mixed lymphocytes reactions, RT-
qPCR, methylation analyzes, histology, assessment of serum
cytokine levels, bioluminescence, and statistical analyses are
described in the supplemental material and method section of
the article. The data sets supporting the conclusions of this arti-
cle are included within this article and its additional ﬁles.
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